On June 18, 2026, a Food and Drug Administration (FDA) advisory panel voted unanimously, 9-0, to recommend the approval of Moderna's mRNA-based flu vaccine, known as mFlusiva, for individuals aged 50 to 64 and those aged 65 and older. The panel concluded that the benefits of the vaccine outweigh the risks for these age groups.
✓ AI-Debiased Article
4
Wire-neutral
provisional
✓ No loaded language, vague sourcing, or framing detected.
FDA Advisory Panel Recommends Approval of Moderna's mRNA Flu Vaccine for Older Adults
An FDA advisory panel has recommended the approval of Moderna's mRNA flu vaccine, mFlusiva, for older adults. The unanimous vote of 9-0 indicates that the panel believes the benefits of the vaccine outweigh its risks for individuals aged 50 and above.
Companies
Moderna
Annotating as
No note attached
on this article.
Original vs. Neutral
Original Headline
FDA panel recommends mRNA flu vaccine for older adults
Neutral Headline
FDA Advisory Panel Recommends Approval of Moderna's mRNA Flu Vaccine for Older Adults